Human Trials - EBC46 Research Hub

Human Trials

Wound Healing After Intratumoral EBC-46 Injection: What Phase I Data Reveals

Phase I trial data shows that wound healing after intratumoral EBC-46 injection follows a predictable pattern, with most treated sites closing within four to six weeks.

Clinical trial setting with medical researcher reviewing patient data in hospital

EBC-46

EBC-46 in Human Clinical Trials: Phase I Safety Data and What It Tells Us

Phase I human trials of tigilanol tiglate are evaluating safety in solid tumours. Early data suggests the tolerability profile mirrors what was observed in veterinary studies.